Related Experiment Video

Updated: Jun 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms

Emmanuele Crespan1, Marco Radi, Samantha Zanoli

  • 1Institute of Molecular Genetics IGM-CNR, via Abbiategrasso 207, 27100 Pavia, Italy.

Bioorganic & Medicinal Chemistry
|May 11, 2010
PubMed

Insights

New dual Src-Abl inhibitors show promise against chronic myelogenous leukemia (CML). Compound BO1 effectively targets drug-resistant AblT315I mutations, offering a potential new therapeutic avenue for CML treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • The tyrosine kinases Src and Abl are crucial in chronic myelogenous leukemia (CML) progression.
  • Imatinib resistance, particularly due to the AblT315I mutation, presents a significant clinical challenge.
  • Currently, no clinically approved inhibitors specifically target the drug-resistant AblT315I mutant.

Purpose of the Study:

  • To kinetically analyze two dual Src-Abl inhibitors against wild-type Src and Abl, and the AblT315I mutant.
  • To evaluate the potency and inhibition mechanism of compound BO1 against these targets.

Main Methods:

  • In vitro kinetic analysis of dual Src-Abl inhibitors.
  • Assessment of inhibitor potency against wild-type Abl, Src, and the AblT315I mutant.
  • Determination of inhibition mechanisms (competitive vs. non-competitive).

Main Results:

  • Compound BO1 demonstrated potent dual inhibition of Src and Abl.
  • BO1 exhibited only a modest fourfold loss in potency against the AblT315I mutant in vitro.
  • BO1 acted as an ATP-competitive inhibitor against wild-type Abl but a non-competitive inhibitor against AblT315I.

Conclusions:

  • Compound BO1 is a potent dual Src-Abl inhibitor with significant activity against the drug-resistant AblT315I mutation.
  • The distinct inhibition mechanism against AblT315I warrants further investigation.
  • BO1 represents a promising candidate for developing novel therapies for CML, including imatinib-resistant cases.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: